Eli Lilly company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
The drugmaker lifted its revenue guidance for the year, pointing to continued strong demand for its obesity and diabetes therapies, sending shares higher in early trading.
THE APEX TIMES
THE APEX TIMES
Investors responded to Eli Lilly’s reported beat-and-raise tied to its GLP-1 franchise, pushing the stock higher on Wednesday.
THE APEX TIMES
Stronger-than-expected results led Lilly’s leadership to look beyond its current weight-loss franchise, with CEO David Ricks citing retatrutide as a potential next growth driver.
THE APEX TIMES
Eli Lilly reported stronger-than-expected results in the second quarter, with revenue momentum tied to its Mounjaro and broader GLP-1 portfolio.
THE APEX TIMES
A roundup of widely followed U.S. equities pointed to a market pulling toward fresh highs even as individual results, including notable moves tied to SpaceX and major semiconductor players, reshaped near-term sentiment.
THE APEX TIMES
CVS Health rallied after reporting a second-quarter earnings beat and lifting its full-year outlook, while also highlighting a partnership with Eli Lilly tied to its weight-loss therapy.
THE APEX TIMES
In its latest quarterly update, Eli Lilly said revenue and net income rose, supported by continued demand for its GLP-1-based therapies used for weight management and related indications.
THE APEX TIMES
The two leading makers of GLP-1-based obesity and diabetes medicines raised their full-year outlooks, indicating that demand has continued to outpace earlier expectations.
THE APEX TIMES
Shares of Eli Lilly (LLY) jumped more than 5% in premarket trading after the company lifted its annual revenue guidance, citing demand for its weight-loss and diabetes therapies.
